Sandbox Reserved 1780

This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795.

To get started: Click the edit this page tab at the top. Save the page after each step, then edit it again. show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page. Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc. More help: Help:Editing

spinqualitylabelsall models Thyroid stimulating hormone receptor bound to thyroid stimulating hormone Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Active and Inactive Form Figure 2: Inactive form of the thyrotropin receptor shown in blue (PDB: 7T9M). Active form of the thyrotropin receptor shown in green (PDB: 7T9I). The TSHR protein exists in two states: active and inactive (Figure 2). The TSHR active form exists in dynamic equilibrium where TSH binding favors the active state. In this active state, TSH will bind and keep the active state in the up position because of clashes between bound TSH and the cell membrane.. TSHR Agonists and Antagonists Chemical agonists are found in many living systems and serve as a way to activate receptors or pathways that are necessary for a wide array of biological processes. Chemical antagonists block or inhibit biological processes. Different types of agonists/antagonists exist within the body including hormones, antibodies, and neurotransmitters. The body naturally produces autoantibodies that can act as agonists and mimic the activating mechanism of the natural hormone.. M22 Agonist M22 is a monoclonal antibody that was isolated from a patient with Graves' Disease. In Graves' disease, autoantibodies mimic TSH function and cause thyroid overactivity. . The M22 autoantibody activates TSHR by causing a membrane clash with the ECD and cell membrane, keeping the TSHR in the active state by preventing the TSHR from rotating to the inactive state (Figure 3). M22 mimics TSH activation of TSHR because it is a potent activator for TSHR. Although M22 binds in a similar manner to TSH, M22 does not interact with the hinge region when bound to TSHR, whereas TSH bound to TSHR does. This finding shows that the hinge region is not necessary for the activation of TSHR, and leads to the discovery of other methods of activation. Figure 3: Agonist and antagonist drugs for activating or inactivating the TSHR protein. CS-17 Inverse Agonist CS-17 is a monoclonal antibody that acts as an inverse agonist for TSHR constitutive activity. . CS-17 interacts with the ECD of the TSHR protein on the convex side of the LRRD. When bound to TSHR, CS-17 suppresses TSHR function by keeping the receptor in the inactive state (Figure 3). Clash with the cell membrane does not allow the inactive form of TSHR to flip to the active conformation. CS-17 plays a unique role with GPCRs. This type of inhibition is not commonly seen in many biological systems and therefore leads to this method of inhibition being a great target for drug design and future research.. Due to its unique inhibition, CS-17 can be a popular therapy for many thyroid diseases where the thyroid is overactive. TSH Agonist This clash is caused by glycosylations of an Asn52 on the α-subunit of TSH. Addition of N-acetyl glucosamine modifications create steric clashes between TSH and the cell membrane, keeping TSHR in the active state.